OCEIREACAIN CAROL PHD

Form 4/A April 01, 2003

SEC Form 4

FORM 4

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility

Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response.....0.5

6. Relationship of Reporting 1. Name and Address of Reporting 2. Issuer Name 4. Statement for Person' and Ticker or Trading Symbol (Month/Day/Year Person(s) to Issuer O'Ceireacain, Carol (Check all applicable) Spectrum Pharmaceuticals, 03/28/2003 X Director _ 10% Owner Inc. (Last) (First) SPPI Officer (give title below) (Middle) _ Other (specify below) 157 Technology Drive 5. If Amendment, 3. I.R.S. Identification Date of Original Description **Board of Director** Number of Reporting (Street) (Month/Day/Year) Person, if an entity Irvine, CA 92618 (voluntary) 7. Individual or Joint/Group 9/30/98 Filing (Check Applicable Line) (City) (State) (Zip) X Form filed by One Reporting Person Form filed by More than One Reporting Person

	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1. Title of Security (Instr. 3)	2.Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (Inst	е	4. Securit n(A) or Dis (Instr. 3	posed	Of (D)	5. Amount of Securities Beneficially Owned Following	6. Owner- ship Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	V	Amount	A/D	Price	Reported Transaction(s) (Instr. 3 and 4)	or Indirect (I) (Instr. 4)		
Common Stock	03/28/2003		J		400 (1)	D	\$0	0	D		

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)													
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/ Day/ Year)	3A. Deemed Execution Date, if any (Month/ Day/	4. Transactio Code (Instr.8)	of Deriva Sec	and tive Expirat urDiætse(ED)	7. Title and (ADTo)unt of Underlying ibSecurities (Instr. 3 and (D4)y/Year)	8. Price of Derivative Security (Instr.5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Owner- ship Form of Deriv- ative Securities: Direct (D)	11. N In B O (II			

Edgar Filing: OCEIREACAIN CAROL PHD - Form 4/A

	Year)		Dispos Of (D) (Inst 3, 4 and 5)						(Instr.4)	or Indirect (I) (Instr.4)		
		Code	>	Α	D	DE	ED	Title	Amount or Number of Shares			

Explanation of Responses:

(1) Spectrum Pharmaceuticals, Inc. loaned \$45,000 for the exercise of a stock option for the purchase of Common Stock on August 31, 1998. On March 28, 2003, the Company forgave/terminated all outstanding amounts due under the loan agreement, and in return, Dr. O'Cleireacain agreed to return the 400 shares of Common Stock orginally purchased under the loan and the shares were subsequently cancelled.

By: Date:

/s/ John L. McManus 04/01/2003

By Power of Attorney for Carol O'Cleireacain, Ph.D.

** Signature of Reporting Person

SEC 1474 (9-02)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not

required to respond unless the form displays a currently valid OMB Number.